News
Medpage Today on MSN1d
FDA Approves Mepolizumab for COPDMepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...
COPD is a group of progressive lung diseases that includes emphysema and chronic bronchitis. Despite affecting an estimated 32 million people in the United States, as many as half are unaware they ...
Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...
MedPage Today on MSN6d
Adding CT, Symptoms Improves COPD DiagnosisThe schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...
We have developed a new, multidimensional diagnostic schema for COPD that incorporates spirometry, symptoms, and imaging and ...
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...
Eucalyptus oil was first used by Aboriginal Australians, who crushed the leaves for their antiseptic properties or steamed ...
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback